Blue Jet Healthcare announces unaudited results for quarter ended September 30, 2026
Blue Jet Healthcare · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited standalone results for the quarter and half year ended September 30, 2026, on November 5, 2026
- Six months ended 30-09-2026: revenue from operations ₹6,688.57 million and profit before tax ₹2,433.40 million
- Allotted 1,58,10,276 equity shares at ₹506 per share under QIP, aggregating ₹8,000.00 million
Why it's rated major development: the year-on-year change is 97% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Financial Results
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other financial results filings this fortnight
- Happy Forgings Ltd announces Q2 FY27 results and Rs. 500 crore capacity expansion
- Sampann Utpadan India Ltd: Sep 30, 2026 quarter standalone loss, half-year profit
- RPSG Ventures Ltd announces unaudited Q2 and H1 FY2026-27 financial results
- LG Electronics India reports Sep 2026 quarter results; approves Vehicle Solutions business
- Uno Minda Limited announces Q2 FY27 results, CEO change, and capacity expansion
- Birla Cable Q2 standalone net profit ₹3781.69 lakh vs ₹69.08 lakh a year earlier
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.